Celltrion Healthcare Co Ltd

KR

Health Care

75900 ₽

Current price

Strong sell
75900 ₽

Target price 00%

Ranks rating

76

  • Position in sub-industry

    151 / 178

  • Position in country

    2123 / 2780

  • Return on Assets, %

    0.8

    2.4

  • Net income margin, %

    6.9

    1.5

  • EBITDA margin, %

    8

    4.6

  • Debt to Equity, %

    17.5

    35.4

  • Intangible assets and goodwill, %

    0.2

    1.8

  • Revenue CAGR 3Y, %

    21.4

    8.3

  • Total Equity change 1Y, %

    -6.5

    0

  • Revenue Y, % chg

    11.4

    1.5

  • P/BV

    5.7

    1.2

  • EV/EBITDA

    40.8

    8.6

  • Dividend Yield, %

    0.1

    2.7

  • Payout Ratio, %

    46.7

    30.7

  • Dividend Ex Date

    2022-12-28

Get an analytical review of this company

Competitors

Ranks

  • Jointown Pharmaceutical Group Co Ltd

    00%

  • Sinopharm Group Co Ltd

    00%

  • Shanghai Pharmaceuticals Holding Co Ltd

    00%

  • Cencora Inc

    00%

  • Cardinal Health Inc

    00%

  • Mckesson Corp

    00%

  • Amplifon SpA

    00%

  • Henry Schein Inc

    00%

  • Celltrion Healthcare Co Ltd

    00%

  • HLB Life Science Co Ltd

    00%

Ready-made portfolio of the best Russian stocks

  • Created by artificial intelligence
  • Verified by analysts
  • Available even to beginners

Company information

  • Country

    Korea; Republic (S. Korea)

  • Sector

    Health Care

  • Industry group

    Health Care Equipment & Services

  • Industry

    Health Care Providers & Services

  • Sub-sector

    Health Care

  • Capitalization (millions of $)

    9500.9

  • Ticker

    091990.KQ

  • ISIN

    KR7091990002

  • IPO date

  • Availability on Russian exchanges

    No

  • Reporting for

    2023-11-14

  • Date fact. publication of reports

    2023-09-30

Company Description

Celltrion Healthcare Co Ltd is a Korea-based company principally engaged in the marketing and distribution of biopharmaceuticals. The Company provides Remsima, an infliximab biosimilar used for the treatment of rheumatoid arthritis, ankylosing spondylitis, adult and child crohn’s disease, psoriasis, psoriatic arthritis and ulcerative colitis. It also offers Truxima, a rituximab biosimilar used for the treatment of non-Hodgkin lymphomas, chronic lymphocytic leukemia and rheumatoid arthritis. The Company distributes its products in domestic and overseas markets.

A step towards better analytics

  • find the best promotions through the Screener
  • keep an eye on stock valuation
  • download detailed reports

and much more after free registration

Registration

More convenient from your phone? Download: